Companies | MenFem

The Index

Companies

400 dossiers · 1 need attention

A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.

Group

Filters1

IndustryAll Agtech15 AI-Bio22 AI & Machine Learning26 Beauty Personal Care1 Biopharma21 Cloud Computing

19 of 400 companies· Neurotech & BCI

Company	Ticker	Beat	Verdict	Call	Coverage	Last looked	Grounding	TR

bci13 names· avg TR 8
Q Quantum-Si	QSI	bci	A first-mover NGPS tools story whose commercial engine is going backwards (revenue −20% in FY25, −69% in Q1'26 to $258K) while it bets the company on Proteus by end-2026; ~$190M cash funds the bet, but a 69%-Rothberg-controlled sub-$1 microcap with collapsing instrument demand is a binary option, not an investment — WATCHING until Proteus ships and consumable pull-through proves real.	—	Fresh	9d	Hybrid	8
M Medtronic	MDT	bci	Cheapest large-cap medtech (fwd P/E ~13x, ~half of BSX/SYK) finally inflecting — PFA + Hugo + an Elliott-forced cost/portfolio reset put a credible re-rating in play, but the whole thesis rests on one unproven number: does organic growth hold above 5%?	—	Fresh	8d	Hybrid	8
K Kernel	—	bci	A genuinely good optical-imaging instrument company wearing three failed business models — capital-starved ($158M total, no priced round since Dec-2023) and IPO-irrelevant while the rest of BCI raises billions; WATCHING, not investable, until a real revenue line or a strategic acquirer appears.	—	Fresh	5d	Web	8
I Inbrain Neuroelectronics	—	bci	The best-positioned European BCI pure-play and the only graphene-native one — but it is a Series-B, pre-revenue spin-off two full funding rounds behind Neuralink/Precision, and its material moat is unproven precisely where its closest competitor (Precision's Layer 7) already has FDA clearance; a watch-and-wait private, not yet investable, gated on a Series C + a graphene-specific regulatory de-risking event.	—	Fresh	5d	Web	8
H Hyperfinecatalyst in 43d	HYPR	bci	A real, FDA-cleared portable-MRI razor finally finding its blade — Q1 device units +67% and runway into 2028 de-risk the going-concern story, but at ~$22M revenue and a ~$140M cap it is still a sub-scale, founder-controlled call option on point-of-care neuro-imaging, not yet a business.	—	Fresh	9d	Hybrid
G g.tec medical engineering	—	bci	The profitable, un-hyped grandfather of non-invasive BCI — a 27-year Austrian bootstrap that quietly owns the research-EEG install base and is turning recoveriX neurorehab into a franchise annuity; a real cash-flowing business but NOT a tradeable IPO candidate (no venture capital, ~$24M est. value, founder-owned), so it is a WATCH-the-category tell, not a position.	—	Fresh	6d	Web	8
F Forest Neurotech	—	bci	Forest is a nonprofit research instrument, NOT an equity — the tradeable BCI bet it incubated walked out the door as Merge Labs (Altman/OpenAI, $850M); track Forest as the science-de-risking front-end, position via Merge or Butterfly (BFLY), never Forest itself.	—	Fresh	6d	Web	8
E Emotiv	—	bci	The most-cited consumer-EEG brand in research, now repricing itself as "cognitive AI infrastructure" — but 23 years in, ~$10M ever raised, and a Chilean supreme-court delete order make it the BCI category's pioneer that capital forgot, not its winner. WATCHING — a be-early IPO-readiness name, not yet investable.	—	Fresh	7d	Web	8
C CorTec	—	bci	The only European bidirectional-BCI in US human trials, backed by the BioNTech family office (Santo/Strüngmann) — a Breakthrough-Device, stroke-rehab-first asset that is structurally early and structurally under-capitalised; WATCHING for the funding round that proves the Strüngmanns will write a BioNTech-scale cheque, not just an option.	—	Fresh	7d	Web	8
C Cognixion	—	bci	A non-invasive, AR-first AAC headset with a real FDA-Breakthrough wedge and two distribution partners — but at a ~$25–46M valuation after 12 years and ~$25–32M raised, it is a mission-driven research-tools / assistive-device niche player, not a venture-scale BCI bet; the asymmetry is acquisition-by-a-giant, not an IPO.	—	Fresh	8d	Web	8
B Butterfly Network	BFLY	bci	A genuine semiconductor moat wrapped around a sub-scale, still-unprofitable medtech — the Midjourney/Embedded licensing pivot is real and re-rates the story, but at ~10x forward sales with episodic licensing revenue and a founder selling, the price already imputes the platform it has not yet proven.	—	Fresh	11d	Hybrid	8
B BrainCo	—	bci	The only at-scale, FDA-cleared, revenue-bearing non-invasive BCI franchise heading to a public listing — but it is a Chinese military-civil-fusion controversy with a confidential HK IPO, no public financials, and a US national-security cloud, so it is un-investable on a US/UK book until it trades and discloses.	—	Fresh	9d	Web	8
A Axoft	—	bci	The softest neural interface on the planet with zero chronic human data — a genuine materials-science lead wrapped around an unproven clinical thesis and a behind-the-pack regulatory position; a WATCH, not a bet, until a Fleuron probe records cleanly past 90 days in a living brain.	—	Fresh	9d	Web	8
bci-neuroscience6 names· avg TR 5
S Synchron	—	bci-neuroscience	The safest, most surgically scalable path into the brain and the only BCI Apple made a native input — but it bet the company on "good enough" 16-electrode bandwidth, and its own third-gen "whole-brain" pivot is a confession that the moat it is famous for may be the ceiling it has to escape.	—	Fresh	11d	Web	8